Dosage-dependent transcriptional regulation by the calcineurin/NFAT signaling in developing myocardium transition  by Yang, Xiao Yong et al.
Developmental Biology 303 (2007) 825–837
www.elsevier.com/locate/ydbioGenomes & Developmental Control
Dosage-dependent transcriptional regulation by the calcineurin/NFAT
signaling in developing myocardium transition
Xiao Yong Yang a, Teddy T.C. Yang a, William Schubert a, Stephen M. Factor b, Chi-Wing Chow a,⁎
a Department of Molecular Pharmacology, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, 1300 Morris Park Ave, Bronx, NY 10461, USA
b Department of Pathology and Medicine, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, Bronx, NY 10461, USA
Received for publication 9 August 2006; revised 9 November 2006; accepted 22 November 2006
Available online 2 December 2006Abstract
Thin spongy myocardium is critical at early embryonic stage [before embryonic day (E) 13.5 in mice] to allow diffusion of oxygen and
nutrients to the developing cardiomyocytes. However, establishment of compact myocardium at later stage (∼E16.5) during development is
necessary to prepare for the increase in demand for blood circulation. Elucidating molecular targets of the spongy–compact myocardium transition
between E13.5 and E16.5 in heart development is thus important. Previous studies demonstrated that multiple transcription factors and signaling
pathways are involved in the regulation and function of the myocardium in heart development. Disruption of certain transcription factors or critical
components of signaling pathways frequently causes structural malformation in heart and persistence of “thin spongy myocardium”. We have
recently demonstrated activation of the calcineurin/NFAT signaling pathway at E14.5 in developing myocardium. Constitutive inhibition of the
calcineurin/NFAT signaling pathway caused embryonic lethality. Molecular targets downstream of the calcineurin/NFAT signaling pathway,
however, remains elusive. Here, we report transcription targets, independently and dependently, regulated by the calcineurin/NFAT signaling
during the E13.5–E16.5 myocardium transition. We have uncovered that expression of one-third of the induced genes during myocardium
transition is calcineurin/NFAT-dependent. Among these calcineurin/NFAT-dependent transcription targets, there is a dosage-dependent regulation.
Molecular studies indicate that formation of distinct NFAT:DNA complex, in part, accounts for the dosage-dependent regulation. Thus, in addition
to temporal and spatial regulation, dosage-dependent threshold requirement provides another mechanism to modulate transcription response
mediated by the calcineurin/NFAT signaling during heart development.
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Heart is the first organ to form during gestation (Kaufman,
1992; Kaufman and Bard, 1999). Multiple transcription factors
and signaling pathways are involved in the regulation and
function of the myocardium in heart development (Bruneau,
2002; Harvey and Rosenthal, 1999; MacLellan and Schneider,
2000; Srivastava, 2001; Srivastava and Olson, 2000). This
process involves proliferation and differentiation of cardiomyo-
cytes, which are regulated in a synchronized and temporal
manner. Many of these signaling pathways are also activated to
compensate for diminished cardiac output and to increase⁎ Corresponding author. Fax: +1 718 430 8922.
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doi:10.1016/j.ydbio.2006.11.036workload of diseased hearts. Thus, understanding the molecular
basis of heart development will shed new light on congenital
heart defects as well as adult heart disease.
Previous gene targeting studies have demonstrated that
disruption of certain transcription factors or critical components
of signaling pathways frequently causes structural malformation
in heart and persistence of “thin spongy myocardium”, which
results in congenital heart defects and causes premature death.
Formation of thin spongy myocardium is critical at early
embryonic stage [before embryonic day (E) 13.5 in mice] to
allow diffusion of oxygen and nutrients to the developing
cardiomyocytes. However, establishment of compact myocar-
dium at later stage (∼E16.5) during development is necessary to
substitute the spongy myocardium to prepare for the increase in
demand for blood circulation. The underlying molecular
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E13.5–E16.5 in heart development, however, has yet to be
established.
The vertebrate specific calcineurin/transcription factor NFAT
signaling pathway regulates gene expression in immune and
non-immune cells (Crabtree and Olson, 2002; Hogan et al.,
2003; Horsley and Pavlath, 2002; Macian, 2005). Previous
studies showed that targeted disruption of NFATc1 impairs heart
valve and septum formation and hence causes embryonic
lethality by E14.5 (de la Pompa et al., 1998; Ranger et al.,
1998). Recent studies further demonstrated a field of endocar-
dium–myocardium interaction is necessary for the induction of
heart valves (Chang et al., 2004). Specifically, repression of
NFAT target – VEGF – provides an instructive role for heart
valve formation.
In addition to heart valve formation, NFATc3 and NFATc4
are required for vasculature development in heart between E7.5
and E8.5 (Bushdid et al., 2003; Graef et al., 2001). Combined
disruption of NFATc3 and NFATc4 causes embryonic lethality.
The requirement of two NFAT members in vasculature
formation implicates a possible functional redundancy and/or
threshold regulation in the calcineurin/NFATsignaling pathway.
The calcineurin/NFAT signaling also plays a key role in
cardiac hypertrophy in adult heart (Molkentin et al., 1998).
Cardiac hypertrophy is frequently associated with reactivation
of fetal genes involved in heart development in the myocardium
(Frey and Olson, 2003; Molkentin and Dorn, 2001; Petrich and
Wang, 2004). Together, these studies elucidate distinct roles
(spatially and temporally) of NFAT in heart development and
disease. However, targets of the calcineurin/NFAT signaling
pathway in cardiac myocytes, which are maturated at later
stages during development, remain elusive.
Recently, we have established transgenic mice expressing
dominant-negative NFAT inhibitor (dnNFAT) in heart (Schubert
et al., 2003). Since constitutive expression of the dnNFAT in
myocardium causes embryonic lethality, we have conditionally
expressed the dnNFAT in heart. We have demonstrated NFAT
activation during myocardium transition at E14.5. Inhibition of
NFAT causes thin myocardium in the developing atria.
Ultrastructural studies demonstrated disrupted sarcomere and
molecular analysis demonstrated reduced expression of cardiac
troponin-I and cardiac troponin-T at birth. Increased expression
of dnNFAT causes more severe deformation in heart and the
majority of transgenic embryos are found dead by E16.5 (data
not shown). Although these studies further demonstrated the
spatial and temporal requirement of the calcineurin/NFAT
signaling, the transcription profile mediated by the calcineurin/
NFAT signaling in the E13.5–E16.5 myocardium transition
remains unknown.
The purpose of this study was to profile molecular targets
and elucidate the contribution of calcineurin/NFAT signaling
during E13.5–E16.5 myocardium transition. Here, we report
transcription targets, independently and dependently, regulated
by the calcineurin/NFAT signaling during the E13.5–E16.5
myocardium transition. We have uncovered that expression of
one-third of the induced genes during E13.5–E16.5 myocardi-
um transition requires calcineurin/NFAT activation. For theexpression of the calcineurin/NFAT-dependent transcription
targets, there is a dosage-dependent threshold regulation.
Formation of distinct NFAT:DNA complex, in part, accounts
for the dosage-dependent regulation. Thus, in addition to
temporal and spatial regulation, threshold requirement provides
another mechanism to modulate transcription response mediat-
ed by the calcineurin/NFAT signaling.
Materials and methods
Mice
Animal experiments were performed in accordance with guidelines of Albert
Einstein College of Medicine Institute of Animal Studies. All mice were in
C57BL/6 background. Timed-pregnant mice were injected subcutaneously with
cyclosporin A daily at 40 mg/kg/day (low dose) and 80 mg/kg/day (high dose)
starting at E13.5. Embryos were harvested on E16.5 and hearts were prepared.
Embryonic heart preparation
Embryonic hearts were harvested at various times during gestation as
indicated. The date after conception was registered as embryonic day (E) 0.5. On
the day of harvest, the embryos were decapitated and the remaining torso was
fixed in 10% buffered formalin overnight before isolation of the hearts through a
dissecting microscope. Isolated hearts were put in cassette and immersed in 70%
alcohol before processed through a graded series of alcohols and xylene in an
automated tissue processor. Isolated hearts were then immersed in paraffin,
oriented and embedded. Embedded hearts were serially sectioned sagittally at a
thickness of 7 μm using a Microm microtome (Baxter Scientific) and placed on
super-frost plus slides (Fisher Scientific). Representative sections were
hematoxylin and eosin-stained and examined under a microscope.
Microarray analysis
Microarray experiments were designed to profile gene expression during
E13.5–E16.5 myocardium transition. Role of calcineurin/NFAT in myocardium
transition was also investigated by subcutaneous injection of calcineurin
inhibitor Cyclosporin A (CsA) into time-pregnant mice starting at E13.5.
Pregnant mice were injected with two different doses of CsA (40 mg/kg/day or
80 mg/kg/day), and embryonic hearts were isolated at E16.5. An Affymetrix
GeneChip Mouse Genome set 430 2.0 array consisting>45,000 probe sets,
representing over 34,000 mouse genes, was used. Total RNA was isolated
separately from hearts of E13.5, E16.5, (E16.5+ low CsA) and (E16.5+high
CsA) using Trizol reagents and purified by Rneasy Fibrous Tissue Mini Kit
(Qiagen). Ten hearts from each condition were pulled together for RNA
preparation. Total RNA (5 μg) of each sample was first reverse transcribed with
T7-oligo (dT) promoter-primer in the first-strand cDNA synthesis using
Superscript II reverse transcriptase. Then RNase H-mediated second strand
cDNA was synthesized by DNA polymerase I. Double-stranded cDNA was
purified and served as a template in the subsequent in vitro transcription
reaction. Complementary RNA (cRNA) was synthesized and biotin labeled
overnight in the presence of T7 RNA polymerase and biotinylated nucleotide
analog/ribonucleotide mix. The biotinylated cRNA targets were then cleaned up,
fragmented and hybridized to GeneChip expression arrays for 16 h. After
washing and staining, the image was scanned and analyzed using Affymetrix
Microarray Suit Software 5.0, which conducted normalization and scaling of the
data. When two arrays were compared, the cRNA expression level of a transcript
was directly proportional to the signal intensity, which was a quantitative value
calculated for each probe. Signal log ratio estimated the magnitude of change
between different arrays. Robust changes were identified by selecting transcripts
with fold change>2 for increase and decrease targets, which corresponded to an
absolute signal log ratio>1. Candidate genes were selected from all profiles (i.e.
E13.5 versus E16.5, or E16.5 hearts:untreated versus CsA treated) with a
difference of>2-fold. In addition, a changing p-value less than or equal to 0.05
must be satisfied, which represented a high probability of significant increase/
decrease between arrays. Candidate genes were verified by RT-PCR based on
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Gene cluster analysis was processed by TMEV (TIGR Multiple
Experiment Viewer) software version 3.1. Signal intensities of the genes
were log10 transformed, then imported into the TMEV software for Gene/
Row adjustments. Gene cluster was generated using Euclidean metric with
complete linkage. The image was colored to represent increase (red) or
decrease (green) in intensity. Pathway analysis was performed by using
pathway-express software of Onto-Tools from Wayne State University, a
derivative of the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database. This modified software allows construction of all
associated signaling pathways based on the gene profile. Affymetrix probe
IDs were input into the software and genes involved in possible signaling
pathways were revealed and categorized (Table 1 and supplemental data
Tables S2–S10).
Semi-quantitative RT-PCR
Total RNA was isolated from embryonic hearts using TRIZOL reagents
(Invitrogen). Isolated RNA (1 μg) was reverse transcribed with Superscript II
reverse transcriptase (Invitrogen), and cDNA prepared was amplified by PCR,
separated and visualized by agarose gel electrophoresis. At least two
amplifications with different cycles were performed. Intensity of PCR products
from three independent experiments was quantified by ImageQuant 5.0 software
(Adobe). Primers for PCR amplification were summarized in Table S1 in
supplemental data.
Morphometric analysis
To determine ventricular wall thickness, digital images of embryonic hearts
were generated. Images were selected based on their similar morphological
appearances containing all four chambers and valves. Using the generated
images, equal distance was extended from the apex to the top of the left and rightTable 1
Transcription targets elicited upon myocardium transition modulate various signalin
Signaling pathways Regulated by
E13.5 vs E16.5 Calcineurin/NFAT
Calcium signaling pathway + −
+ ++
+ +
Wnt signaling pathway + −
+ ++
+ +
Notch signaling pathway + −
+ ++
+ +
Ligand–receptor interaction + −
+ ++
+ +
Tight junction + −
+ ++
+ +
Focal adhesion + −
+ ++
+ +
Adherens junction + −
+ ++
+ +
Cytokine–cytokine
receptor interaction
+ −
+ ++
+ +
Complement and
coagulation cascades
+ −
+ ++
+ +ventricles along the circumference of the heart. A total of eight different
locations were marked. Thickness of each location along the ventricular walls
was measured from 10 images. The averages were then graphed and presented.
Gel mobility shift assays
Nuclear extracts were prepared from cells transfected with NFAT expression
vector as described previously (Yang and Chow, 2003; Yang et al., 2002). In
brief, double-stranded oligonucleotides (100 fmol) were labeled with [α-32P]
dCTP using DNA polymerase I Klenow fragments. Binding reactions for gel
mobility shift assays were carried out at RT in gel-shift buffer [1 mM CaCl2,
1 mMMgCl2, 10 mMHepes (pH 7.9), 50 mMNaCl, 15 mMβ-mercaptoethanol,
10% glycerol, 0.1 mg/ml bovine serum albumin, and 1 mg/ml poly dI:dC] for
30 min. Protein:DNA complexes were separated in 5% non-denaturing
polyacrylamide gels in Tris–glycine–EDTA buffer [25 mM Tris, 200 mM
glycine, and 1 mM EDTA] and visualized by autoradiography. For supershift
analysis, antibodywas pre-incubated with nuclear extract for 30min at RT before
addition of the labeled probe. For competition analysis, excess amount of
unlabeled IL-2 NFAToligonucleotides (5000 fmol, or 500, 1000, and 2500 fmol
of different competitors for cross-competition analysis) were incubated together
with the labeled probe before addition of the nuclear extract. To determine the
relative binding of the NFAT:DNA complex, saturation analysis was performed.
In brief, increasing amount of labeled probe (50, 100, and 150 fmol) was
incubated with constant amount of nuclear extract. The amount of NFAT:DNA
complexes and unbound probe were quantitated by PhosphoImager analysis. The
ratio of bound/free was plotted against the amount of bound and presented.
Sequence for the NFATsites of the Agtr2 andReg3γ promoter is (Agtr2:−701 bp
5′-CAG-AGAAAAGGAAAAACAGTCATAACCATA-3′; −1951 bp 5′-
GTTTCCTAGACATCA-GGTTTCCATTATTTA-3′; −5251 bp 5′-GTATTT-
GTGGCAAGTTTTCCCAGACTGTAT-3′; Reg3γ: −201 bp 5′-ATAG-
TATCTGGGAAAA-GATGGGGAAAGTTC-3′; −251 bp 5′-TATGTTCCG-
GAAAACTTATAGAAATAATAG-3′). Sequence for the interleukin-2 ARRE
NFAT is (5′-AGAAAGGAGGAAAAACTGTTTCATA-CAGAAGG-3′).g pathways
Target genes
Cacna1g, Ryr2, Prkcb1, Mylk, Adcy9, Atp2a3, Tnnt1, Casq2, Fhl2
Tnnc2, Lck, Camk4, Ptprc, Myh3
Cckar, Myh8, Fkbp5
Myc, Wif1, Prkcb1, Wnt5a
Rac2, Lef1
Tcf7
Dtx1
Ptcra
Lepr, P2rx1, Agtr, Rgs5, Oprl1
Pery10, Gzma
Agtr2, Cckar, Gpr64, Angptl1, C1qtnf3, Reg3g
Cldn5, Cldn7, Cldn8, Crb3, Prkcb1, Hcls1
Cldn18
Cldn3, Cldn10
Vav1, Vtn, Parvg, Col1a1, ltga7, Cav1, Cav2, App1, Mylk, Flnb4
Coro1a, Eva1, Pscdbp
Col11a1
Cdh1, Lef1, Hcph, Rac2
Tcf7
lL1f2, Amhr2, Tnfsf11, Tslp, Lepr
lL7, Ccl25, Cxcl10, lL2ra, Ltb, Cxcl15, Ccr9
Cxcl13, Gdf10
C1S, F13a1, C3
F3, Anxa8
Fig. 1. Dosage–responsive reduction of E16.5 myocardium walls upon NFAT
inhibition by cyclosporin A. Timed-pregnant mice were given low and high
dosage of cyclosporin A (CsA). Hearts isolated from untreated and CsA-treated
embryos were fixed in 10% formalin, processed, embedded, and serial sectioned
sagittally. Representative sections, from at least 10 embryos in two different
litters, were shown (panel A). Cross-sectional thickness of ventricular walls,
from 10 different embryos, were measured (panel B). Scale bar=200 μm.
*p≤0.05; †p≤0.005.
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Dosage–responsive reduction of myocardium walls upon NFAT
inhibition by cyclosporin A
We have recently demonstrated that calcineurin/NFAT is
required for the late morphogenesis (after E14.5) of heart
maturation (Schubert et al., 2003). Inhibition of NFAT activity
by conditional expression of a dominant negative inhibitor
(dnNFAT) in heart leads to thin atrial myocardium and
sarcomere disorganization. Increase expression of dnNFAT,
however, causes more severe deformation in both chambers and
the majority of transgenic embryos are found dead by E16.5
(data not shown). These data are corroborated by the
observation that constitutive expression of the dnNFAT in
myocardium caused embryonic lethality (data not shown).
Together, these data indicate that the calcineurin/NFAT
signaling pathway contributes significantly to the myocardium
transition. Further elucidating the expression of downstream
targets of the calcineurin/NFAT signaling pathway is important.
To circumvent the embryonic lethality of the dnNFAT
transgenic mice, we utilized calcineurin inhibitor cyclosporin A
(CsA) to block NFAT activation in vivo. CsA blocks calcineurin
activation and thus, impedes subsequent NFAT nuclear
localization and function. We administered CsA subcutaneously
to time-pregnant C57BL/6 mice from E13.5 to E16.5 to block
calcineurin activation during myocardium transition. Injection
of CsA starting at E13.5 will thus bypass the inhibition on
vasculature formation and heart valve differentiation. Two
different doses of CsA (low, 40 mg/kg/day; high, 80 mg/kg/day)
were administered, in the range of CsA used in previous studies
(Bueno et al., 2002; Gafter-Gvili et al., 2003; Zhang, 2002), to
ascertain efficacy of delivery to developing embryos and to
allow full extent of calcineurin inhibition.
We performed histological analysis on E16.5 hearts of
C57BL/6 mice given or not CsA starting on E13.5. Histological
analysis of E16.5, CsA-treated hearts revealed thinning in their
atrial and ventricular myocardium as compared to untreated
hearts (Fig. 1A). Importantly, a dosage-dependent reduction of
the myocardium thickness was observed upon CsA adminis-
tration. Morphometric analysis of the myocardium thickness
revealed a graded reduction of the ventricular walls upon CsA
administration (Fig. 1B). These data indicate that a dosage-
dependent threshold regulation of the calcineurin/NFAT
signaling pathway by CsA inhibition leads to a gradual thinning
in the developing myocardium. In addition, these data support
that heightened NFAT inhibition leads to more severe heart
deformation and embryonic lethality.
Transcription profile during myocardium transition
Next, we investigated the molecular targets mediated by the
calcineurin/NFAT signaling during myocardium transition. To
profile the molecular targets during myocardium transition, we
performed microarray analysis to determine gene expression in
hearts isolated from E13.5 and E16.5 embryos. Differentially
expressed targets found at these stages would likely play acritical role in myocardium transition. In addition, RNA isolated
from E16.5, cyclosporin A (CsA)-treated hearts were also
subjected to microarray analysis to elucidate the contribution of
calcineurin/NFAT signaling in myocardium transition.
Four transcription profiles were analyzed: E13.5, E16.5, and
E16.5 treated with low or high dosage of CsA. Transcription
profile from E13.5 heart was cross compared with transcription
profile from E16.5 heart (E16.5 versus E13.5) to identify
developmentally regulated genes that might play a role in
myocardium transition. Similarly, transcription profile from
untreated E16.5 hearts was cross compared with transcription
profile from E16.5 hearts treated with low or high dosage of
CsA, [(E16.5: untreated versus low CsA) and (E16.5: untreated
versus high CsA)], to identify calcineurin-regulated genes. Data
mining analysis was further performed by contrasting of the
transcription profiles between (E16.5 versus E13.5) and (E16.5:
untreated versus low CsA) or (E16.5: untreated versus high
CsA) to identify developmental transcription targets that are
calcineurin/NFAT-dependent during myocardium transition
(Fig. 2, also in supplemental data Figs. S1–S4).
With a filter for fold changes >2, our microarray analysis
demonstrated that expression of 878 genes were increased and
260 genes were decreased during E13.5–E16.5 myocardium
transition (Figs. 2 and 3). Upon CsA inhibition, 388 genes were
increased and 277 genes were decreased in E16.5 hearts.
Among all the differential expressed genes during E13.5–E16.5
myocardium transition, 278 of increased genes and 13 of
decreased genes were sensitive to CsA inhibition. Hence, about
one-third of increased genes (278/878) during myocardium
Fig. 2. Transcription profile during myocardium transition. Schematic representation of microarray analysis. Total RNA isolated from embryonic day (E) 13.5, E16.5,
and E13.5–E16.5 cyclosporin A (CsA)-treated hearts [low (Lo) and high (Hi) dosage] were reverse transcribed, labeled, and hybridized to Affymetrix 430 2.0 array
DNA chips. Transcription profiles of myocardium transition from E13.5 to E16.5 (E13.5 versus E16.5), and untreated E16.5 heart versus CsA treated E16.5 heart
(E16.5: Untreated versus Lo CsA and E16.5: Untreated versusHi CsA) were examined. Hatched boxes represent E13.5–E16.5 regulated genes. Shaded or filled boxes
represent calcineurin/NFAT-regulated genes. Darker shade represents higher amount of CsA is required to regulate these transcription targets. Number of genes
changed is also indicated and is represented by filled arrows (up, increased genes; down, decreased genes). Number of genes that are differentially regulated by high,
but not low, dosage of CsA is highlighted.
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pathway. Conversely, the calcineurin/NFAT signaling only
modestly regulated gene reduction (13/260) during myocardium
transition. Expression of the remaining 600 increased genes and
247 decreased genes was independent of calcineurin/NFAT
regulation during E13.5–E16.5 myocardium transition. Among
the 278 calcineurin/NFAT increased and 13 decreased genes,
expression of 44 increased genes and 7 decreased genes were
inhibited only at high CsA concentration. Clustering analysis
further demonstrated that these 44 differentially regulated genes
(Fig. 3D) exhibited different induction profile as compared to the
remaining 234 genes, which were sensitive to both high and low
CsA concentration (Fig. 3B). Together, these data reveal
transcription profiles, which are calcineurin/NFAT dependent
and independent, during myocardium transition. In addition,
there is a dosage-dependent threshold regulation for the trans-
cription of some calcineurin/NFAT-dependent molecular targets.
Data mining analysis further indicated that transcription
targets elicited upon myocardium transition could be classified
into various signaling pathways. These included calcium
signaling pathway, Wnt signal transduction, and many
ligand–receptor interactions (Table 1). Notably, gene targets
involved in cell–cell contact (e.g. tight junction and focal
adhesion) were also modulated upon myocardium transition.
Presumably, secure cell–cell contact is required to provide
communication (e.g. calcium mobilization) as well as synchro-
nized contraction in the mature myocardium upon stimulation.
Calcineurin/NFAT-independent transcription regulation during
myocardium transition
To validate differential expression of the identified molecular
targets during E13.5 and E16.5 myocardium transition, we
performed RT-PCR analysis. We selected a handful of represen-
tative genes (Tables 2 and 3) based on i) ESTexpression profile in
heart, ii) EST expression profile during gestation, and/or iii)
potential function in heart. RT-PCR analysis demonstrated that
increased expression of acyl-CoA synthetase long-chain family
member 1 (Ascl1), calsequestrin 2 (Casq2), creatine kinasemitochondrial 2 (Ckmt2), cytochrome c oxidase subunit VIIa1
(Cox7a1), cytochrome c oxidase subunit VIIIb (Cox8b), fatty
acid binding protein 4 (Fabp4), four and a half LIM domains 2
(Fhl2), myomesin 2 (Myom2), regulator of G-protein signaling 5
(Rgs5), and S100 calcium binding protein A1 (S00A1) (Figs. 4A
and B), whereas expression of EGF-like repeats and discoidin I-
like domain 3 (Edil3), heparin sulfate 6-O-sulfotransferase 2
(Hs6st2), opioid receptor-like 1 (Oprl1), slow skeletal troponin
T1 (Tnnt1); and wingless-related MMTV integration site 5A
(Wnt5a) were decreased (Figs. 4C and D) during E13.5–E16.5
myocardium transition. Transcription of all these differentially
expressed genes, however, were calcineurin/NFAT-independent
as their expression levels were similar in the presence and
absence of CsA treatment. Expression of glyceraldehydes-3-
phosphate dehydrogenase (Gapdh) and ribosomal protein L32
(Rpl32) were used as controls. These data support the microarray
analysis for the differential expression of molecular targets.
Transcription targets regulated by the calcineurin/NFAT
signaling during myocardium transition
We also performed RT-PCR to ascertain the differential
regulation of molecular targets that were calcineurin/NFAT-
dependent. RT-PCR analysis demonstrated that increased exp-
ression of angiotensin I converting enzyme 2 (Ace2), carbo-
xylesterase 3 (Ces3), coronin, actin binding protein 1A (Coro1a),
deltex 1 homolog (Dtx1), keratin complex 2, basic gene 8 (Krt2-
8), lymphoid enhancer binding factor 1 (Lef1), NADPH dehyd-
rogenase quinone 1 (Nqo1), secretoglobin family 1A, member 1
(Scgb1a1), secretoglobin family 3A, member 1 (Scgb3a1), trans-
cription factor 7 (Tcf7), and transformation related protein 63
(Trp63) upon E13.5–E16.5 myocardium transition (Figs. 5A and
B). Induction of these genes, however, was abrogated by low or
high CsA inhibition. We also uncovered molecular targets that
were calcineurin/NFAT-dependent, but independent of E13.5–
E16.5 myocardium transition (Figs. 5C and D). Examples in this
group of transcription targets were lymphocyte cytosolic protein
1 (Lcp1) and Ras association domain family 5 (Rassf5). Similar
expression of Gapdh was used as control.
Fig. 3. Clustering analysis of genes regulated by the calcineurin/NFAT signaling during myocardium transition. A) Signal intensities of 234 increased genes that were
CsA dependent from E13.5 to E16.5 were analyzed by TMEV (TIGR Multiple Experiment Viewer) and presented. Expression levels were colored coordinated with
green for low intensity and red for high intensity. B) Expression pattern of the 234 increased genes indicated inhibition by CsA at low and high dosages. C) Signal
intensities of 44 increased genes that were CsA threshold dependent were presented. D) Expression pattern of the 44 increased genes indicated that these genes were
more sensitive to high dosage of CsA inhibition during E13.5–E16.5 myocardium transition.
830 X.Y. Yang et al. / Developmental Biology 303 (2007) 825–837Dosage-dependent threshold requirement on transcription
targets regulated by the calcineurin/NFAT signaling during
myocardium transition
Unexpectedly, increased expression of some calcineurin/
NFAT-dependent targets during E13.5–E16.5 myocardiumtransition were blocked by CsA inhibition only at high, but
not low, concentration (Fig. 6). These threshold-sensitive genes
included angiotensin II receptor type 2 (Agtr2), carbonyl
reductase 2 (Cbr2), cytochrome P450 family 2, subfamily f,
polypeptide 2 (Cyp2f2), forkhead box A1 (Foxa1), regenerating
islet-derived 3 gamma (Reg3γ), and SRY-box containing gene 2
Table 2
Transcription targets during myocardium transition—calcineurin/NFAT-
independent
Gene title Gene symbol Fold Δ Unigene ID
E13.5–E16.5 transition, CsA independent up-regulated genes
Acyl-CoA synthetase long-chain
family member 1
Ascl1 4.3 a Mm.210323
Calsequestrin 2 Casq2 2.3 Mm.15343
Creatine kinase, mitochondrial 2 Ckmt2 7.0 Mm.316438
Cytochrome c oxidaase subunit VIIa1 Cox7a1 2.1 Mm.12907
Cytochrome c oxidaase subunit VIIIb Cox8b 4.6 Mm.3841
Fatty acid binding protein 4 Fabp4 2.6 Mm.582
Four and a half LIM domains 2 Fhl2 2.1 Mm.6799
Myomesin 2 Myom2 9.2 Mm.272115
Regulator of G-protein signaling 5 Rgs5 2.6 Mm.20954
S100 calcium binding protein A1 S100A1 2.0 Mm.24662
E13.5–E16.5 transition, CsA independents down-regulated genes
EGF-like repeats and discoidin
I-like domain 3
Edil3 −2.8 Mm.125580
Herapin sulfate 6-0-sulfotransferase 2 Hs6st2 −2.3 Mm.252561
Opioid receptor-like 1 Oprl1 −2.3 Mm.285075
Slow skeletal troponin T1 Tnnt1 −3.2 Mm.358643
Wingless-related MMTV integration
site 5A
Wnt5a −2.6 Mm.287544
a E16.5 vs E13.5.
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Together, these data demonstrate that the calcineurin/NFAT
signaling plays a critical role in transcription induction during
myocardium transition. In addition, these data demonstrate a
dosage-dependent threshold regulation of the calcineurin/NFAT
targets.
Expression of components of calcineurin/NFAT signaling
pathway during myocardium transition
Dosage-dependent threshold regulation of the calcineurin/
NFAT signaling pathway may, in part, be due to changes in the
expression level of calcineurin phosphatases [calcineurin
phosphatase catalytic subunit Aα and Aβ (CnAα, and
CnAβ), and calcineurin regulatory subunit B (CnB)], NFAT
members (NFATc1–c4), and endogenous calcineurin inhibitors
Cabin and calcipressin (Csp1–3) (Ryeom et al., 2003), also
known as modulatory calcineurin-interacting protein (MCIP) or
Down syndrome critical region (DSCR) (Kingsbury and
Cunningham, 2000; Rothermel et al., 2000; Rothermel et al.,
2003; Vega et al., 2003). RT-PCR analysis demonstrated that the
expression of CnAα, CnAβ, and CnB were similar at E13.5 and
E16.5 hearts (Fig. 7). Their expression level was not affected by
CsA inhibition. Similarly, the expression level of calcineurin
inhibitor Cabin and calcipressin (Csp 1–3) was similar. The
expression level of NFAT members (NFATc1–c4) was also
similar, except NFATc2 exhibited potential alternative spliced
isoforms at E13.5. These data demonstrate that the expression
of components of the calcineurin/NFAT signaling pathway is
similar during myocardium transition. Alterations in intracellu-
lar calcium and subsequent activation of the calcineurin/NFAT
signaling pathway is likely to account for the threshold
regulation.Formation of NFAT:DNA complex of the Agtr2 and Reg3γ
gene
Transcription targets identified by using microarray analysis
could be regulated directly or indirectly by the calcineurin/
NFAT signaling. NFAT may directly bind to the identified
targets and modulate gene transcription. Previous studies
indicated that the canonical NFAT element from the interleu-
kin-2 (IL-2) gene is a composite enhancer containing NFAT and
AP-1 (Fos and Jun) (Jain et al., 1992). On the other hand, C/
EBP is present in the proximal NFAT site of the peroxisome
proliferator-activated receptor-γ2 (PPARγ2) gene (Yang and
Chow, 2003). Sequence analysis indicated that there are three
putative NFAT binding sites (GGAAA) in the Agtr2 promoter
(Fig. 8A). These NFAT binding sites are located at −701,
−1951, and −5251 bp upstream of the Agtr2 promoter.
However, little similarity was found in the adjacent sequence
for NFAT partners (AP1 or C/EBP) (Fig. 8B). These
observations indicate that Agtr2, a dosage-dependent regulated
NFAT target, may be directly regulated by NFAT with partners
other than AP1 or C/EBP.
We performed gel mobility shift assays to investigate the
formation of NFAT:DNA complex of the Agtr2 NFAT binding
elements (Fig. 8C). All three NFAT binding elements of the
Agtr2 gene formed NFAT:DNA complexes, indicating that
NFAT directly regulates Agtr2 gene. Specificity of the NFAT:
DNA complexes was confirmed by supershift analysis using
antibody against NFAT and competition analysis using excess
amount of unlabeled canonical NFAT site from the IL-2 gene.
Interestingly, the Agtr2 NFAT:DNA complex exhibited in-
creased electrophoretic mobility as compared to the IL-2 NFAT:
DNA complex. Electrophoretic mobility of NFAT:DNA
complex similar to the one found in the Agtr2 gene was also
detected using the NFAT binding elements from the Reg3γ
gene, another dosage-dependent regulated NFAT target contain-
ing NFAT binding elements at −201 and −251 bp upstream of
the promoter (Fig. 8). Together, these data indicate that NFAT
directly regulates Agtr2 and Reg3γ gene.
The NFAT sites at −701 bp and −1951 bp of the Agtr2 gene
and −251 bp of the Reg3γ exhibited increased formation of
NFAT:DNA complex (Fig. 8C). Increased intensity suggest
formation of a more stable NFAT:DNA complex, which may in
part due to abundance of NFAT partners or increased affinity in
protein–protein/protein–DNA interactions between NFAT,
NFAT partner, and DNA. Next, we investigated the relative
binding of different NFAT sites from the IL-2, PPARγ2, Agtr2,
and Reg3γ gene by saturation analysis (Fig. 8D). NFAT binding
sites from the IL-2 and PPARγ2 gene were selected for
comparison because their NFAT partners (AP1 and C/EBP)
were both b-ZIP type transcription factors (Jain et al., 1992;
Yang and Chow, 2003). Scatchard analysis indicated the relative
binding avidity in the NFAT:DNA complex from the Agtr2 and
Reg3γNFATsites was decreased as compared to the NFAT:AP1
of IL-2 gene and the NFAT:C/EBP of PPARγ2 gene (Fig. 8D).
These data indicate that changes in relative binding avidity
cannot account for the increased NFAT:DNA complex forma-
tion in the Agtr2 and Reg3γ NFAT sites.
Table 3
Transciption targets during myocardium transition—calcineurin/NFAT-dependent
Gene title Gene symbol Fold Δ Unigene ID
E13.5–E16.5 transition, CsA dependent up-regulated genes
Angiotensin I converting enzyme 2 Ace2 55.0 a 1.7 b 1.7 c Mm.13451
Carboxylesterase 3 Ces2 27.8 5.6 2.0 Mm.292803
Coronin, actin binding protein 1A Coro1a 7.0 7.5 9.2 Mm.290482
Deltex 1 homolog Dtx1 3.7 2.8 2.1 Mm.1645
Keratin complex 2, basic gene 8 Krt2-8 7.0 6.1 8.6 Mm.358618
Lymphoid enhancer binding factor 1 Lef1 2.6 4.3 9.2 Mm.255219
NADPH dehydrogenase quinone 1 Nqo1 2.8 2.0 2.0 Mm.252
Secretoglobin family 1A, member 1 Scgb1a1 48.5 8.0 90.5 Mm.2258
Secretoglobin family 3A, member 1 Scgb3a1 14.9 5.7 11.3 Mm.22802
Transcription factor 7 Tcf7 11.3 16.0 16.0 Mm.31630
Transformation related protein 63 Trp63 7.0 16.0 4.0 Mm.20894
E13.5–E16.5 transition, CsA threshold up-regulated genes
Angiotensin II receptor type 2 Agtr2 24.3 1.1 5.7 Mm.2679
Carbonyl reductase 2 Cbr2 36.7 2.8 45.2 Mm.21454
Cytochrome P450 Family 2, subfamily f, polypeptide 2 Cyp2f2 45.3 2.1 42.2 Mm.4515
Forkhead box A1 Foxa1 8.0 2.5 68.6 Mm.4578
Regenerating islet-derived 3 gamma Reg3g 111.4 3.5 42.2 Mm.252385
SRY-box containing gene 2 Sox2 3.7 2.6 36.7 Mm.4541
E13.5–E16.5 transition independent, CsA dependent up-regulated genes
Lymphocyte cytosolic protein 1 Lcp1 ND 2.1 2.1 Mm.153911
Ras association domain family 5 Rassf5 ND 2.1 1.9 Mm.248291
a E16.5 vs E13.5.
b E16.5: Untreated vs Lo CsA.
c E16.5: Untreated vs Hi CsA.
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Reg3γ NFAT sites exhibit reduced binding avidity, we
performed cross competition analysis (Fig. 8E). Formation of
NFAT:DNA complex by the IL-2 NFAT site was reduced by self
competition using unlabeled oligonucleotides. At five times
excess of competitors in self competition, ∼10% NFAT:DNA
complex remained bound to the IL-2 NFAT:AP1 site. At 10
times excess of competitors in self competition, formation of
NFAT:DNA complex on the IL-2 NFAT:AP1 site was hardly
detected. At least ∼50% of IL-2 NFAT:DNA complex,
however, remained bound even in the presence of 25 times
excess of unlabeled Agtr2 or Reg3γ NFAT sites as competitors.
Conversely, the amount of NFAT:DNA complex formed by the
Agtr2 or Reg3γ NFAT probes was competed to a similar extent
by the IL-2 NFAT sites or by self competition. These data
confirm that the relative binding avidity from the Agtr2 and
Reg3γNFATsites is reduced as compared to the NFAT:AP1 site
of the IL-2 gene. Together, the increase in electrophoretic
mobility and the difference in relative binding avidity indicate
that formation of distinct NFAT:DNA complexes, in part,
accounts for the dosage-dependent regulation mediated by the
calcineurin/NFAT signaling.
Discussion
Molecular targets in E13.5–E16.5 myocardium transition
In this report, we have profiled transcription targets during
E13.5–E16.5 myocardium transition. Coupling with calcineurinspecific inhibitor — cyclosporin A (CsA), we have further
identified genes regulated dependently and independently by
the calcineurin/NFAT signaling pathway. Our results demon-
strated that about a-third of the induced genes during E13.5–
E16.5 myocardium transition is regulated by the calcineurin/
NFAT signaling pathway. Among the calcineurin/NFAT regu-
lated genes, there is a dosage-dependent regulation of their
expression. Dosage-dependent calcineurin/NFAT inhibition is
also revealed by a graded disruption in heart morphogenesis.
Together, these results demonstrate a critical role for the
calcineurin/NFAT signaling pathway in heart development.
Among the calcineurin/NFAT targets, structural genes [e.g.
coronin, actin binding protein 1A (Coro1a), and keratin
complex 2, basic gene 8 (Krt2-8)] and molecular targets
involved in mitochondrial biogenesis [e.g. carboxylesterase 3
(Ces3), NADPH dehydrogenase quinone 1 (Nqo1), carbonyl
reductase 2 (Cbr2), and cytochrome P450 family 2, subfamily f,
polypeptide 2 (Cyp2f2)] are identified. Identification of these
structural genes and mitochondrial targets support the role of
NFAT in cellular architecture and redox regulation (Bushdid
et al., 2003).
In addition to the structural genes and mitochondrial targets,
secretory factors, such as members of the secretoglobin (Scgb)
family, are revealed in this study. Members of the secretoglobin
family are critical for regulation of lung function (Cassel et al.,
2002; Reynolds et al., 2002). Interestingly, lung morphogenesis
takes place after heart formation (Kaufman, 1992; Kaufman and
Bard, 1999). The expression of Scgb proteins in embryonic
heart and their functions in lung morphogenesis suggest a
Fig. 4. Calcineurin/NFAT-independent transcription regulation during myocar-
dium transition. A–B) RT-PCR analysis to illustrate transcription targets that
were increased, but calcineurin/NFAT-independent, during E13.5 to E16.5
myocardium transition (panel A). Two different dosages of CsA were used to
probe the requirement of calcineurin/NFAT during myocardium transition.
Expression of Gapdh (glyceraldehydes-3-phosphate dehydrogenase) and Rpl32
(ribosomal protein L32) were used as controls. Quantification of PCR products
using ImageQuant software was also shown (panel B). Ascl1, Acyl-CoA
synthetase long-chain family member 1; Casq2, Calsequestrin 2; Ckmt2,
Creatine kinase mitochondrial 2; Cox7a1, Cytochrome c oxidase subunit VIIa1;
Cox8b, Cytochrome c oxidase subunit VIIIb; Fabp4, Fatty acid binding protein
4; Fhl2, Four and a half LIM domains 2; Myom2, Myomesin 2; Rgs5, Regulator
of G-protein signaling 5; and S00A1, S100 calcium binding protein A1. C–D)
RT-PCR analysis to illustrate transcripton targets that were decreased, but
calcineurin/NFAT-independent, during E13.5 to E16.5 myocardium transition
(panel C). Quantification of PCR products using ImageQuant software was also
shown (panel D). Edil3, EGF-like repeats and discoidin I-like domain 3; Hs6st2,
Heparin sulfate 6-O-sulfotransferase 2; Oprl1, Opioid receptor-like 1; Tnnt1,
Slow skeletal troponin T1; and Wnt5a, Wingless-related MMTV integration site
5A.
Fig. 5. Transcription targets regulated by the calcineurin/NFAT signaling during
myocardium transition. A–B) RT-PCR analysis to illustrate calcineurin/NFAT-
dependent transcription targets that were increased during E13.5 to E16.5
myocardium transition (panel A). Two different dosages of CsA were used to
probe the requirement of calcineurin/NFAT during myocardium transition.
Expression of Gapdh (glyceraldehydes-3-phosphate dehydrogenase) and Rpl32
(ribosomal protein L32) were used as controls. Quantification of PCR products
using ImageQuant software was also shown (panel B). Ace2, Angiotensin I
converting enzyme 2; Ces3, Carboxylesterase 3; Coro1a, Coronin, actin binding
protein 1A; Dtx1, Deltex 1 homolog; Krt2-8, Keratin complex 2, basic gene 8;
Lef1, Lymphoid enhancer binding factor 1; Nqo1, NADPH dehydrogenase
quinone 1; Scgb1a1, Secretoglobin family 1A, member 1; Scgb3a1,
Secretoglobin family 3A, member 1; Tcf7, Transcription factor 7; and Trp63,
Transformation related protein 63. C–D) RT-PCR analysis to illustrate
transcription targets that were sensitive to CsA inhibition, but are not regulated
upon E13.5–E16.5 myocardium transition (panel C). Quantification of PCR
products using ImageQuant software was also shown (panel D). Lcp1,
Lymphocyte cytosolic protein 1; Rassf5, Ras association domain family 5.
Fig. 6. Dosage-dependent threshold requirement on transcription targets
regulated by the calcineurin/NFAT signaling during myocardium transition.
A–B) RT-PCR analysis to illustrate transcription targets that were only sensitive
to high dosage of CsA inhibition during E13.5–E16.5 myocardium transition
(panel A). Expression of Gapdh (glyceraldehydes-3-phosphate dehydrogenase)
was used as a control. Quantification of PCR products using ImageQuant
software was also shown (panel B). Agtr2, Angiotensin II receptor type 2; Cbr2,
Carbonyl reductase 2; Cyp2f2, Cytochrome P450 Family 2, subfamily f,
polypeptide 2; Foxa1, Forkhead box A1; Reg3γ, Regenerating islet-derived 3
gamma; and Sox2, SRY-box containing gene 2.
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during development.
Regenerating islet-derived 3 gamma (Reg3γ), another
secretory factor, is regulated by the calcineurin/NFAT signaling
pathway in a threshold-dependent manner. Requirement of high
inhibition to block Reg3γ expression suggests that a minimal
calcineurin/NFAT activity is sufficient for the transcription
induction during myocardium transition. This minimal require-
ment implicates that Reg3γ is critical for myocardium
transition. Members of the Reg family were identified as
critical mitogens for regeneration/proliferation in various
tissues (Okamoto, 1999; Terazono et al., 1988). Myocardium
transition, similar to regeneration, requires mitogenic factors to
stimulate proliferation and remodeling. Since diseased heart
exhibits characteristics of embryonic heart and reactivates fetal
gene program, and the calcineurin/NFAT signaling pathway is
Fig. 7. Expression of components of the calcineurin/NFAT signaling pathway
during myocardium transition. A–B) RT-PCR analysis to examine the
expression level of components of the calcineurin/NFAT signaling pathway
during E13.5 to E16.5 myocardium transition (panel A). CsA-treated hearts
were also examined. Quantification of PCR products using ImageQuant
software was also shown (panel B). CnAα, calcineurin phosphatase catalytic
subunit Aα; CnAβ, calcineurin phosphatase catalytic subunit Aβ; CnB,
calcineurin regulatory subunit B; Csp, calcipressin.
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members may be up-regulated for possible heart “regeneration”
after insult. Thus, cardiomyocytes expressing Reg mitogen may
be molecular markers for characterizing potential multipotent
cells in heart during recovery, in addition to its potential role
during myocardium transition. A goal for future studies is to
elucidate the role of Reg members in cardiac stem cells and in
heart development.
In addition, dosage-dependent regulation of the expression
of angiotensin II receptor type 2 (Agtr2) is of interest. Agtr2 is
expressed mainly in developing myocardium and hypertrophic
heart (Grady et al., 1991; Wang et al., 1998). Similar to Reg3γ,
minimal Agtr2 expression is detected after birth and in normal
adult heart. Previous studies demonstrated that transgenic mice
expressing Agtr2 in heart leaded to dosage-dependent cardio-
myopathy and dysregulation in heart function (Nakayama et al.,
2005; Yan et al., 2003). Hence, the extent of NFAT activation
and its subsequent gene transcription may directly correlate
with heart function.
Here, we have demonstrated that the calcineurin/NFAT
signaling pathway regulates the expression of one-third of the
induced genes during myocardium transition. Transcription
regulation of the remaining two-third, however, remains to be
identified. Signaling pathways that may involve in the transcrip-Fig. 8. Formation of NFAT:DNA complex of the Agtr2 and Reg3γ gene. A) Schemati
indicated by filled triangles. B) Sequence comparison of the NFAT binding sites in IL
illustrated (filled box). Adjacent NFAT partner binding site was also indicated (AP-1,
that resemble the AP-1 (*) or C/EBP (^) binding sequence were also indicated. C) Fo
NFAT:DNA complexes (open triangles) from IL-2, Reg3γ, and Agtr2 NFAT sites we
were competed by excess amounts of unlabeled canonical NFAT binding element f
different NFAT sites. IL-2 NFAT:AP1 site (open squares on dotted line) and PPARγ2
Agtr2 NFAT sites (at −701 bp: filled squares on solid line; at −1951 bp: filled trian
Average linear correlation coefficient of each probe in the data set is ≥0.94. Slope
presented. Amount of bound NFAT:DNA complex and free DNA probe was quantita
amount of bound and graphed. E) Cross-competition analysis to assess NFAT DNA
NFAT binding elements as competitors (500, 1000, 2500 fmol) were incubated w
autoradiography.tion regulation of the remaining two-third of genes may include
the G-protein coupled receptor (GPCR) pathway, TGFβ/BMP
signal transduction, and Tyr receptor kinase signaling (Brand and
Schneider, 1995; Negro et al., 2004; Rockman et al., 2002;
Wetzker and Rommel, 2004). Certain targets during myocardium
transition may also be co-regulated by different signaling
pathways. Contribution of these additional pathways in modulat-
ing myocardium transition may be assessed by similar reduction-
ist approach using specific inhibitors in microarray analysis to
identify differentially expressed targets.
Dosage-dependent threshold regulation of the
calcineurin/NFAT-mediated gene transcription
The calcineurin/NFAT signaling pathway was first charac-
terized in immune models (Crabtree and Olson, 2002; Hogan et
al., 2003; Horsley and Pavlath, 2002; Macian, 2005).
Subsequent studies have extended the calcineurin/NFAT
regulation and function to non-immune cells. In this report,
we have demonstrated that a dosage-dependent requirement
plays a role in calcineurin/NFAT-mediated gene transcription
during myocardium transition. Mechanistically, formation of
distinct NFAT:DNA complexes, in part, accounts for the
differential regulation. Similar dosage-dependent requirement
for the calcineurin/NFAT signaling pathway has been reported
in regulating immune function (Ryeom et al., 2003). Hence,
dosage-dependent regulation provides another means for
modulating calcineurin/NFAT-mediated gene transcription.
Transcription factor NFAT constantly shuttles between
nucleus and cytoplasm (Kehlenbach et al., 1998; Shibasaki et
al., 1996). Continuous shuttling between the nuclear and
cytoplasmic compartment may provide a “partial” activation
state and allow subsequent transcription of the dosage-sensitive
target genes. Upon elevation in intracellular calcium, calci-
neurin-mediated dephosphorylation favors NFAT nuclear
import. Dephosphorylation, which is illustrated by substantial
increase in electrophoretic mobility, has been served as a
hallmark for NFAT activation (Chow et al., 1997; Loh et al.,
1996; Yang et al., 2002). If transcription of dosage-sensitive
targets only requires minimal calcineurin/NFAT activity, the
basal, transiently resided nuclear NFAT in resting cells would
be sufficient for their expression. Hence, complete dephos-
phorylation and the substantial increase in electrophoretic
mobility may not be required for certain NFAT-mediated gene
transcription.c illustration of the Agtr2 and the Reg3γ promoter. NFAT binding elements were
-2, PPARγ2, Reg3γ and Agtr2 gene promoters. Canonical NFAT-binding site is
shaded box; C/EBP, hatched box). Residues on the Reg3γ and Agtr2 NFAT sites
rmation of distinct NFAT complexes on the Reg3γ and Agtr2-binding elements.
re supershifted with antibody against NFAT (asterisks). NFAT:DNA complexes
rom the IL-2 gene. D) Saturation analysis to determine the relative binding of
NFAT:C/EBP site (open circles on dotted line) were used for comparison to the
gles on solid line), and Reg3γ −251 bp NFAT site (filled circles on solid line).
of the graph represents relative binding avidity of different NFAT probes and
ted by PhosphoImager analysis. The ratio of bound/free was plotted against the
binding in IL-2, Agtr2, and Reg3γ NFAT sites. Increasing amount of unlabeled
ith the indicated probe. Formation of NFAT:DNA complex was visualized by
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NFAT partners to form a composite binding elements for gene
regulation. For example, AP-1 (Fos+Jun) are NFAT partners on
the IL-2 gene (Jain et al., 1992). The NFAT:DNA complexes
from the Agtr2 and the Reg3γ gene exhibit increased
electrophoretic mobility as compared to that from the IL-2
gene, suggesting that partners other than AP-1 cooperate with
NFAT to regulate gene expression. Since the NFAT:DNA
complexes are separated by non-denaturing gel electrophoresis,
the partners of Agtr2 and Reg3γ gene may be lower in molecular
weight or enriched in acidic amino acid residues. Alternatively, a
more compact ordered arrangement may be found in the NFAT:
DNA complexes of the Agtr2 and the Reg3γ gene.
In addition to the increase in electrophoretic mobility, certain
NFAT:DNA complexes from the Agtr2 (Agtr2 −701 bp and
−1951 bp) and the Reg3γ (Reg3γ −251 bp) gene exhibit
increase in intensity as compared to that from the IL-2 gene.
Increased intensity suggest formation of a more stable NFAT:
DNA complex, which may in part due to the abundance of
NFAT partners or increased affinity in protein–protein/protein–
DNA interactions between NFAT, NFAT partner, and DNA.
Since the Agtr2 and Reg3γ NFAT sites exhibit reduced relative
binding avidity as compared to the IL-2 NFAT:AP1 site, it is
likely that the abundance of partners for the Agtr2 and Reg3γ
NFAT sites accounts for the increased formation of NFAT:DNA
complex. Binding of different partners exerts another layer of
regulation on NFAT-mediated gene transcription. Hence,
activation of dosage-dependent regulated genes is possibly
due to efficient cooperation between NFAT and its highly
expressed partners. Identification of such NFAT partners is an
immediate goal to further elucidate regulation of NFAT-
mediated gene transcription in heart function.
We have demonstrated that the expression levels of
components of the calcineurin/NFAT signaling pathway are
similar during myocardium transition. These components
include calcineurin phosphatases (CnAα, CnAβ, CnB), calci-
neurin inhibitors (Cabin, and Csp1–3), and NFAT (NFATc1–
c4). We surmise that alterations in intracellular calcium and
subsequent activation of the calcineurin/NFAT signaling
pathway are likely to account for the dosage-dependent
regulation. A recent report, indeed, indicated that a 1.5 fold
change in the expression of a NFAT kinase – Dyrk1a – may be
sufficient to cause Down's syndrome (Arron et al., 2006).
Dyrk1a kinase opposes the accumulation of nuclear NFAT
(Arron et al., 2006; Gwack et al., 2006). Hence, the duration in
the nucleus is a critical parameter for the dosage-dependent
threshold regulation mediated by NFAT.
In addition to NFAT, many other transcription factors are also
regulated by nuclear/cytoplasmic shuttling mechanism (Cart-
wright and Helin, 2000; Smith and Koopman, 2004). Their
“partial/transient” localization in the nucleus may be sufficient
to modulate gene transcription in a dosage-dependent manner.
Since minimal basal activity is sufficient for the expression of
these dosage-sensitive targets, these genes are likely to be the
rate-limiting components or essential genes. Further identifica-
tion and characterization of these threshold-sensitive targets are
warranted.Conclusion
In conclusion, we have demonstrated that the calcineurin/
NFAT signaling contributes to the expression of one-third of
genes during the E13.5–E16.5 myocardium transition. Expres-
sion of the calcineurin/NFAT-dependent transcription target is,
in part, regulated by a dosage-dependent threshold mechanism.
Thus, in addition to temporal and spatial control, dosage-
dependent regulation provides another mechanism to modulate
transcriptional response mediated by the calcineurin/NFAT
signaling.
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